Back to discover

Protein / target

Leukocyte immunoglobulin-like receptor subfamily B member 1

Encoded byLILRB1Q8NHL6Homo sapiensSwiss-Prot
1
Research papers

Protein at a glance

Biological role

HLA-A specific inhibitory MHC class I receptor

Strongest disease association

Epstein-Barr Virus Infections

Via encoding gene LILRB1 · Genetic evidence · score 0.34

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for class I MHC antigens.

View complete UniProt function annotation

Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:19304799, PubMed:29262349). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251)

Subcellular location

Cell membraneSecreted
Domains and Gene Ontology detail (58)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Ig-like C2-type 4

Gene Ontology

  • Ccytoplasm
  • Cexternal side of plasma membrane
  • Cextracellular region
  • Cplasma membrane
  • FHLA-A specific inhibitory MHC class I receptor activity
  • FHLA-B specific inhibitory MHC class I receptor activity
  • Finhibitory MHC class I receptor activity
  • FMHC class I protein binding
  • FMHC class I receptor activity
  • FMHC class Ib protein binding
  • FMHC class Ib protein complex binding
  • FMHC class Ib receptor activity

650 aa · 71 kDa · 5 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGOTranscriptional regulationGOApoptosis & cell deathGO
View supporting evidence

Immune signalling

  • ·adaptive immune response
  • ·immune response-inhibiting cell surface receptor signaling pathway
  • ·interleukin-10-mediated signaling pathway
  • ·negative regulation of alpha-beta T cell activation

Transcriptional regulation

  • ·positive regulation of gene expression
  • ·positive regulation of transcription by RNA polymerase II

Apoptosis & cell death

  • ·negative regulation of dendritic cell apoptotic process
  • ·positive regulation of apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene LILRB1

Gene-level evidence surfaced through the gene LILRB1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Epstein-Barr Virus Infections
0.35Limited support

Genetic evidence dominant · Open Targets 0.21

Miyoshi myopathy
0.13Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

Neoplasms
0.12Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

Arthritis, Rheumatoid
0.12Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

Stomach Neoplasms
0.12Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

View evidence synthesis (5)
Epstein-Barr Virus InfectionsLimited support
0.35
agreement 0.210.49
Genetic97%Literature3%

Open Targets aggregate 0.21 · 2 independent evidence families

Miyoshi myopathyPreliminary
0.13
agreement 0.000.40
Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

NeoplasmsPreliminary
0.12
agreement 0.000.40
Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

Arthritis, RheumatoidPreliminary
0.12
agreement 0.000.31
Literature94%RNA expression6%

Open Targets aggregate 0.09 · 2 independent evidence families · no direct causal or clinical evidence

Stomach NeoplasmsPreliminary
0.12
agreement 0.000.39
Literature100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Epstein-Barr Virus Infections0.21
Miyoshi myopathy0.10
Neoplasms0.10
Stomach Neoplasms0.09
Arthritis, Rheumatoid0.09
Lupus Erythematosus, Systemic0.09
Leukemia, Myeloid, Acute0.09
Glioblastoma0.09

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.